AR062925A1 - METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS - Google Patents

METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS

Info

Publication number
AR062925A1
AR062925A1 ARP070104166A ARP070104166A AR062925A1 AR 062925 A1 AR062925 A1 AR 062925A1 AR P070104166 A ARP070104166 A AR P070104166A AR P070104166 A ARP070104166 A AR P070104166A AR 062925 A1 AR062925 A1 AR 062925A1
Authority
AR
Argentina
Prior art keywords
pharmacologically active
active agents
tablets containing
containing pharmacologically
manufacturing tablets
Prior art date
Application number
ARP070104166A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR062925A1 publication Critical patent/AR062925A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Abstract

Un método para mejorar las propiedades físicas de una forma de dosificacion oral solida, en especial una tableta, utiliza un lubricante externo durante el proceso de compactacion. La forma de dosificacion oral solida comprende un agente farmacologicamente activo, por ejemplo una proteína o polipéptido, y un agente de suministro. Empleando el método, se mejoran las propiedades de la tableta, tales como dureza, tiempo de desintegracion, y disolucion.A method to improve the physical properties of a solid oral dosage form, especially a tablet, uses an external lubricant during the compaction process. The solid oral dosage form comprises a pharmacologically active agent, for example a protein or polypeptide, and a delivery agent. Using the method, the properties of the tablet are improved, such as hardness, disintegration time, and dissolution.

ARP070104166A 2006-09-22 2007-09-20 METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS AR062925A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82659706P 2006-09-22 2006-09-22

Publications (1)

Publication Number Publication Date
AR062925A1 true AR062925A1 (en) 2008-12-17

Family

ID=39227036

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104166A AR062925A1 (en) 2006-09-22 2007-09-20 METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS

Country Status (5)

Country Link
AR (1) AR062925A1 (en)
CL (1) CL2007002724A1 (en)
PE (1) PE20080845A1 (en)
TW (1) TW200820993A (en)
WO (1) WO2008039351A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
ES2690553T3 (en) 2012-03-22 2018-11-21 Novo Nordisk A/S GLP-1 peptide compositions and preparation of these
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
EP3542790B1 (en) 2012-03-22 2023-09-13 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070496A4 (en) * 1998-04-08 2004-07-21 Kyowa Hakko Kogyo Kk Tablet manufacturing method and tablet
US20070065505A1 (en) * 2003-07-11 2007-03-22 Shoufeng Li Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Also Published As

Publication number Publication date
TW200820993A (en) 2008-05-16
PE20080845A1 (en) 2008-08-13
CL2007002724A1 (en) 2008-05-16
WO2008039351A2 (en) 2008-04-03
WO2008039351A3 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
AR062925A1 (en) METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS
CY1118661T1 (en) PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCEDURE FOR THEIR PREPARATION, METHODS FOR TREATMENT AND USE OF THESE
CR10349A (en) FAST LIBERATION PARACETAMOL TABLETS
GT201300309A (en) MODIFIED RELEASE OF 4-METHYL-3 - [[4- (3-PYRIDINYL) -2- PYRIMIDINYL] -AMINO] -N- [5- (4-METHYL -1H-IMIDAZOL-1-IL) -3- (TRIFLUORO -METIL) -PENYL] -BANZAMIDE SOLUBILIZED USING ORGANIC ACIDS
MY150626A (en) Fast dissolving solid dosage form
ECSP088490A (en) ORAL PHARMACEUTICAL FORM THAT CONTAINS AS ACTIVE PRINCIPLES A PROTON PUMP INHIBITOR TOGETHER WITH ACETILSALICYL ACID
ECSP066584A (en) PROCEDURE FOR THE PRODUCTION OF A SOLID PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION
EA201001577A1 (en) DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PRODUCTION
ECSP10010416A (en) PHARMACEUTICAL DOSAGE FORM
AR062644A1 (en) FLOATING PROGRAMMABLE SUPPLY TECHNOLOGY
RS52831B (en) Buprenorrphine wafer for drug substitution therapy
PE20140854A1 (en) PHARMACEUTICAL DOSAGE FORMS
PE20140255A1 (en) DISPERSIBLE TABLET IN ORAL FORM
UY30535A1 (en) COMPOSITION UNDERSTANDING ANTIRRETROVIRAL PHARMACOS AND AT LEAST AN INSOLUBLE WATER POLYMER, PREPARATION PROCESS AND APPLICATIONS.
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
AR063538A1 (en) TREATMENT OF PARKINSON'S DISEASE
PE20150773A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF PHENYLEPHRINE
MY191875A (en) Solid dosage form
PE20110943A1 (en) SOLID ORAL FORMULATION OF ALISQUIREN
TR200900879A2 (en) Pharmaceutical compositions in which the active ingredients are combined in a single dosage form
PE20130147A1 (en) PHARMACEUTICAL COMBINATION OF THEOBROMINE AND A NON-OPIOID ANTITUSSIVE AGENT
UY30126A1 (en) A NEW PHARMACEUTICALLY ACCEPTABLE SALT OF 2-HIDROXI-3- (5- (MORFOLIN-4-ILMETIL) -PIRIDIN-2-L) 1H-INDOL-5-CARBONITRILE, PROCEDURES FOR THE PREPARATION, COMPOSITIONS CONTAINING IT AND APPLICATIONS
IL250852B (en) Periodontal composition
CL2011000614A1 (en) Solid oral dosage form comprising alisquirene alone or in combination with another active agent; Preparation process; and use in the treatment of diseases such as hypertension, angina, atherosclerosis, among others.
BRPI0507985A (en) piperazine urea derivatives for the treatment of endometriosis

Legal Events

Date Code Title Description
FB Suspension of granting procedure